FirmaIQ
Org.nr 985 889 635 2021 → 2022 Year-over-year analysis

LYTIX BIOPHARMA ASA: årsregnskap 2022 vs 2021

Shrank 33% on revenue, cash halved-plus

approved 2023-04-18; registry 2023-08-08; journal 2023 657797

Full company analysis · All year comparisons

Summary

What changed

Comparing Årsregnskap 2022 with 2021 for LYTIX BIOPHARMA ASA. Revenue 25.83m NOK → 17.27m NOK (-33.1%). Net result -48.05m NOK → -56.01m NOK. Equity 189.62m NOK → 135.13m NOK.

Pressures included: revenue fell; operating result weakened; net result weakened.

Also worth watching: paid-in equity reduced; headcount (årsverk) changed. All figures are taken from the published annual accounts for LYTIX BIOPHARMA ASA.

At a glance

Scorecard

Revenue
25.83m NOK 17.27m NOK
-33.1%
Operating result
-48.02m NOK -65.70m NOK
-36.8%
Net result
-48.05m NOK -56.01m NOK
-16.6%
Equity
189.62m NOK 135.13m NOK
-28.7%
Cash
197.28m NOK 94.55m NOK
-52.1%
Total assets
202.96m NOK 152 NOK
-100.0%

What deteriorated

  • ↓

    Revenue fell

    Operating income / revenue moved from 25.83m NOK to 17.27m NOK (-33.1% YoY). Calculated

  • ↓

    Operating result weakened

    Operating result -48.02m NOK → -65.70m NOK (op. margin -185.9% → -380.3%). Calculated

  • ↓

    Net result weakened

    Net result -48.05m NOK → -56.01m NOK (net margin -186.0% → -324.2%). Calculated

  • ↓

    Equity eroded

    Book equity 189.62m NOK → 135.13m NOK (equity ratio 93.4% → 88898684.2%). Calculated

  • ↓

    Cash fell

    Bank deposits 197.28m NOK → 94.55m NOK (-52.1% YoY). Calculated

Things to notice

  • ·

    Paid-in equity reduced

    Paid-in equity fell 189.62m NOK → 135.13m NOK — check capital reduction, conversion, or reclassification. Interpretation

  • ·

    Headcount (årsverk) changed

    Reported FTEs 8.3 → 8.5. Reported fact